3 days Ago By ABMN Staff
Accolade, Inc. ( NASDAQ:ACCD – Get Free Report ) saw a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 4,860,000 shares, a drop of 5.
3% from the October 15th total of 5,130,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is presently 3.9 days.
Analyst Upgrades and Downgrades ACCD has been the subject of a number of analyst reports. Stephens cut their price target on Accolade from $10.00 to $8.
00 and set an “overweight” rating for the company in a research note on Wednesday, October 9th. Truist Financial cut their price target on Accolade from $9.00 to $7.
50 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Accolade in a research note on Monday, October 7th.
Canaccord Genuity Group cut their price target on Accolade from $13.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th.
Finally, Barclays cut their price target on Accolade from $5.50 to $5.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 9th.
Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.04.
Check Out Our Latest Stock Analysis on ACCD Institutional Investors Weigh In On Accolade Accolade Price Performance Accolade stock opened at $3.38 on Tuesday. Accolade has a 52 week low of $3.
08 and a 52 week high of $15.36. The company’s 50 day moving average price is $3.
69 and its two-hundred day moving average price is $4.69. The company has a quick ratio of 2.
72, a current ratio of 2.72 and a debt-to-equity ratio of 0.49.
The stock has a market cap of $272.23 million, a P/E ratio of -3.37 and a beta of 2.
02. Accolade ( NASDAQ:ACCD – Get Free Report ) last posted its earnings results on Tuesday, October 8th. The company reported ($0.
30) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.14.
The firm had revenue of $106.40 million for the quarter, compared to analysts’ expectations of $104.87 million.
Accolade had a negative net margin of 18.16% and a negative return on equity of 18.43%.
The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.
43) EPS. On average, equities analysts predict that Accolade will post -0.92 earnings per share for the current year.
Accolade Company Profile ( Get Free Report ) Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians. See Also Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.
com's FREE daily email newsletter ..
